Home
HelpTest Code CERAM MI-Heart Ceramides, Plasma
Reporting Name
MI-Heart Ceramides, PPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Useful For
Evaluating the risk of major adverse cardiovascular events within the next 1 to 5 years
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Specimen Required
Patient Preparation: Patients should not be receiving Intralipid because it may cause false elevations in measured ceramides.
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge, aliquot at least 1 mL of plasma into a plastic vial and freeze within 8 hours.
Specimen Type
Plasma EDTASpecimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma EDTA | Frozen (preferred) | 30 days | |
| Refrigerated | 24 hours | ||
| Ambient | 8 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | OK |
Reference Values
MI-Heart Ceramide Risk Score:
0-2 Lower risk
3-6 Moderate risk
7-9 Increased risk
10-12 Higher risk
Ceramide (16:0): 0.19-0.36 mcmol/L
Ceramide (18:0): 0.05-0.14 mcmol/L
Ceramide (24:1): 0.65-1.65 mcmol/L
Ceramide (16:0)/(24:0): <0.11
Ceramide (18:0)/(24:0): <0.05
Ceramide (24:1)/(24:0): <0.45
Reference values have not been established for patients who are less than 18 years of age.
Note: Ceramide (24:0) alone has not been independently associated with disease and will not be reported.
Interpretation
Elevated plasma ceramides are associated with increased risk of myocardial infarction, acute coronary syndromes, and mortality within 1 to 5 years.
|
Ceramide Score |
Relative Risk |
Risk Category |
|
0-2 |
1.0 |
Lower |
|
3-6 |
1.5 |
Moderate |
|
7-9 |
2.2 |
Increased |
|
10-12 |
3.5 |
Higher |
Score is based on trial data including >4000 subjects.
Day(s) Performed
Monday, Wednesday, Friday
Report Available
2 to 7 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
0119U
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CERAM | MI-Heart Ceramides, P | 93883-7 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 42434 | MI-Heart Ceramide Risk Score | 93876-1 |
| 42428 | Ceramide (16:0) | 93882-9 |
| 42429 | Ceramide (18:0) | 93881-1 |
| 42430 | Ceramide (24:1) | 93880-3 |
| 42431 | Ceramide (16:0)/(24:0) ratio | 93879-5 |
| 42432 | Ceramide (18:0)/(24:0) ratio | 93878-7 |
| 42433 | Ceramide (24:1)/(24:0) ratio | 93877-9 |
Forms
If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.